We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
+10.89%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$338M
AUM Growth
+$104M
Cap. Flow
+$99.8M
Cap. Flow %
29.5%
Top 10 Hldgs %
45.78%
Holding
65
New
30
Increased
14
Reduced
12
Closed
7

Top Buys

Rank Stock Value
1
TGTX icon
TG Therapeutics
TGTX
+$16.7M
2
PFE icon
Pfizer
PFE
+$8.64M
3
AKRO
Akero Therapeutics
AKRO
+$8.47M
4
JNJ icon
Johnson & Johnson
JNJ
+$8.07M
5
QURE icon
uniQure
QURE
+$7.87M

Top Sells

Rank Stock Value
1
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$25.2M
2
QQQ icon
Invesco QQQ Trust
QQQ
+$13.3M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$10.9M
4
APLS
Apellis Pharmaceuticals
APLS
+$7.81M
5
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$6.02M

Sector Composition

Rank Sector Weight
1 Healthcare 78.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FOLD
26
DELISTED
Amicus Therapeutics
FOLD
$5.27M 1.56%
+475,000
New +$5.85M
MRTX
27
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$5.21M 1.54%
140,000
-60,000
-30% -$2.7M
PTGX icon
28
Protagonist Therapeutics
PTGX
$9.06B
$5.17M 1.53%
+225,000
New +$3.78M
VRDN icon
29
Viridian Therapeutics
VRDN
$1.99B
$4.45M 1.32%
175,000
+10,000
+6% +$321K
ISEE
30
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$4.26M 1.26%
175,000
-275,000
-61% -$6.02M
MLTX icon
31
MoonLake Immunotherapeutics
MLTX
$1.64B
$4.17M 1.23%
+195,000
New +$3.28M
JBIO
32
Jade Biosciences
JBIO
$1.27B
$4.03M 1.19%
5,714
+1,857
+48% +$1.54M
BMEA icon
33
Biomea Fusion
BMEA
$92.5M
$3.72M 1.1%
+120,000
New +$1.49M
ACRS icon
34
Aclaris Therapeutics
ACRS
$793M
$3.44M 1.02%
+425,000
New +$5.39M
APLS
35
CALL
DELISTED
Apellis Pharmaceuticals
APLS
$3.42M 1.01%
+51,900
New +$2.99M
KRTX
36
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$3.18M 0.94%
17,500
-22,500
-56% -$4.3M
ETNB
37
DELISTED
89bio
ETNB
$3.05M 0.9%
+200,000
New +$2.61M
BCRX icon
38
BioCryst Pharmaceuticals
BCRX
$2.36B
$2.29M 0.68%
275,000
+50,000
+22% +$481K
AMAM
39
DELISTED
Ambrx Biopharma Inc
AMAM
$2.23M 0.66%
+250,000
New +$1.26M
RAIN
40
DELISTED
Rain Oncology Inc. Common Stock
RAIN
$2.19M 0.65%
+250,000
New +$2.31M
IRON icon
41
Disc Medicine
IRON
$2.91B
$2.12M 0.63%
+100,000
New +$2.23M
RNAM
42
DELISTED
Avidity Biosciences
RNAM
$1.92M 0.57%
125,000
+25,000
+25% +$550K
ALT icon
43
CALL
Altimmune
ALT
$558M
$1.69M 0.5%
+400,000
New +$4.75M
RXDX
44
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$1.61M 0.48%
15,000
+5,104
+52% +$587K
ALPN
45
DELISTED
Alpine Immune Sciences Inc
ALPN
$1.54M 0.46%
+200,000
New +$1.59M
ETNB
46
CALL
DELISTED
89bio
ETNB
$1.52M 0.45%
+100,000
New +$1.3M
RCUS icon
47
Arcus Biosciences
RCUS
$3.44B
$1.37M 0.4%
+75,000
New +$1.43M
FUSN
48
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$1.32M 0.39%
+350,000
New +$1.38M
WHWK
49
Whitehawk Therapeutics
WHWK
$192M
$1.09M 0.32%
150,000
+60,000
+67% +$641K
TARS icon
50
Tarsus Pharmaceuticals
TARS
$2.61B
$1.01M 0.3%
80,000
– –
1
2
3

Similar funds

SF
Susquehanna Foundation Bala Cynwyd, Pennsylvania $333M AUM 35.73% 1-Year Est. Return
AFS
Annapolis Financial Services Annapolis, Maryland $338M AUM 23.49% 1-Year Est. Return
SFA
Source Financial Advisors New York $338M AUM 33.62% 1-Year Est. Return
E
ETFidea Syracuse, New York $316M AUM 29.57% 1-Year Est. Return
OHCM
Oak Hill Capital Management New York $310M AUM 17.23% 1-Year Est. Return
MC
Minot Capital Broomfield, Colorado $353M AUM 25.25% 1-Year Est. Return
BRA
Biechele Royce Advisors Fishers, Indiana $303M AUM 20.64% 1-Year Est. Return
S
Syntrinsic Denver, Colorado $301M AUM 27.27% 1-Year Est. Return

Ghost Tree Capital's Q1 2023 Portfolio in Review

As of Q1 2023, Ghost Tree Capital held 65 positions worth $338M, up 44% from $234M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Ghost Tree Capital deployed $99.8M of net new capital in Q1 2023, opening 30 new positions and adding to 14 existing holdings. Its largest new stake was TG Therapeutics: 1,100,000 shares worth $16.5M.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, down from 94% a quarter earlier.

On the sell side, the largest reduction was Reata Pharmaceuticals, Inc. Class A Common Stock, an estimated $25.2M trimmed.

  • Ghost Tree Capital's largest Q1 2023 buy was TG Therapeutics: 1,100,000 shares worth $16.5M.
  • Ghost Tree Capital added most to Akero Therapeutics in Q1 2023, an estimated $8.47M increase.
  • Ghost Tree Capital's biggest Q1 2023 reduction was Reata Pharmaceuticals, Inc. Class A Common Stock, cutting an estimated $25.2M.
  • Ghost Tree Capital fully exited Invesco QQQ Trust in Q1 2023, selling an estimated $13.3M.
  • Ghost Tree Capital's ten largest holdings make up 46% of its $338M portfolio in Q1 2023.
  • Ghost Tree Capital opened 30 new positions and closed 7 in Q1 2023.
  • Ghost Tree Capital's portfolio value rose 44% quarter-over-quarter to $338M.

Based on Ghost Tree Capital's 13F filing for Q1 2023, filed 15 May 2023.